Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
576 Leser
Artikel bewerten:
(2)

Lumenis Ltd.: Lumenis and Baring Private Equity Asia to Accelerate Investment in Aesthetics and Vision Verticals Following the Strategic Sale of Lumenis Surgical for $1.07B

- Strong investment in R&D, new business, global sales, and employees

- 'Exciting move toward a bright future' for a leader in dual market domains

YOKNEAM, Israel and HONG KONG, Sept. 1, 2021 /PRNewswire/ -- Lumenis, a global leader in energy-based medical devices for minimally invasive aesthetic and vision applications, announced today the completion of the sale of its Surgical business to Boston Scientific Corporation, a leading global medical device manufacturer, in a transaction valued at $1.07B.

Lumenis_Logo

Lumenis will refocus and accelerate planned investments to support the development of its fast-growing Aesthetic and Vision businesses, emphasizing R&D, global sales and marketing channels, and business development activities.

"After the strategic sale of Lumenis Surgical, we now have a mission to move Lumenis forward in the Aesthetics and Vision markets through strong investment in Lumenis' gold-standard technologies, innovation and employees," said BPEA Managing Director Yan Jiao. "BPEA is looking ahead not only to expanding Lumenis' existing capabilities but also to pursuing new strategic growth opportunities."

"Completion of this deal and transfer of the Surgical business to Boston Scientific - including its robust product portfolio, global team, and the Israeli surgical laser center of excellence - represents a major milestone and a testament to the outstanding work of the Surgical team. Today signals an exciting move toward a bright future for everyone here at Lumenis," commented Lumenis CEO Tzipi Ozer-Armon.

"We have developed and introduced multiple groundbreaking technological solutions for Aesthetics and Vision that have redefined our industry and opened entirely new market segments. We now look towards building on this success by accelerating the expansion of our Aesthetics and Vision businesses. We will also be investing in and growing our exceptional global teams, who have made innovation and market leadership our company's defining traits."

Added Ozer-Armon, "Lumenis remains as committed as ever to the premium level of quality, service, and excellence that our Aesthetics and Vision customers, partners, and patients have come to expect. In the months and years to come, we plan to significantly increase our investment in these domains and build upon our gold-standard portfolio of solutions through the introduction of new and innovative products, services, and digital capabilities."

With a legacy spanning over 50 years in the Aesthetic and Vision domains, Lumenis is an undisputed leader. Lumenis, now more than ever, has a vast portfolio of products that offer exceptional solutions to address multiple evolving needs of physicians and patients.

To learn more about Lumenis and explore careers, visit www.lumenis.com.

For further details please contact:

Scherf Communications
Anat Paz
+972 50 7202715
anat@scherfcom.com

About Lumenis

Lumenis is a premier global inventor and manufacturer of energy-based medical devices for minimally invasive aesthetic and vision applications. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including intense pulsed light (IPL), Lumenis has introduced groundbreaking products, redefined medical treatments and set numerous technological and clinical gold standards for nearly 50 years. Lumenis has created solutions for previously untreatable conditions, as well as designed advanced technologies that revolutionized existing treatment methods.

Logo: http://mma.prnewswire.com/media/541530/Lumenis_Logo.jpg

© 2021 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.